TTY Biopharm Co Ltd - Asset Resilience Ratio

Latest as of December 2025: 4.12%

TTY Biopharm Co Ltd (4105) has an Asset Resilience Ratio of 4.12% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

NT$467.74 Million

≈ $14.74 Million USD Cash + Short-term Investments

Total Assets

NT$11.35 Billion

≈ $357.53 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how TTY Biopharm Co Ltd's Asset Resilience Ratio has changed over time. Check TTY Biopharm Co Ltd strategic asset allocation index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down TTY Biopharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see TTY Biopharm Co Ltd market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$467.74 Million	4.12%
Total Liquid Assets	NT$467.74 Million	4.12%

Asset Resilience Insights

Limited Liquidity: TTY Biopharm Co Ltd maintains only 4.12% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

TTY Biopharm Co Ltd Industry Peers by Asset Resilience Ratio

Compare TTY Biopharm Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Alkem Laboratories Limited NSE:ALKEM	Drug Manufacturers - Specialty & Generic	31.91%
Shan Dong Dong-E E-Jiao Co Ltd SHE:000423	Drug Manufacturers - Specialty & Generic	20.44%
Alkermes plc F:8AK	Drug Manufacturers - Specialty & Generic	3.76%
Jilin Aodong Pharmaceutical Group Co Ltd SHE:000623	Drug Manufacturers - Specialty & Generic	4.97%
Kangmei Pharmaceutical Co Ltd SHG:600518	Drug Manufacturers - Specialty & Generic	0.00%
Shanghai Haoyuan Chemexpress Co. Ltd. A SHG:688131	Drug Manufacturers - Specialty & Generic	1.37%
Fujian Cosunter Pharmaceutical Co Ltd SHE:300436	Drug Manufacturers - Specialty & Generic	-2.56%

Annual Asset Resilience Ratio for TTY Biopharm Co Ltd (2017–2025)

The table below shows the annual Asset Resilience Ratio data for TTY Biopharm Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	4.12%	NT$467.74 Million ≈ $14.74 Million	NT$11.35 Billion ≈ $357.53 Million	+1.28pp
2024-12-31	2.84%	NT$309.01 Million ≈ $9.74 Million	NT$10.86 Billion ≈ $342.24 Million	+0.86pp
2023-12-31	1.98%	NT$195.54 Million ≈ $6.16 Million	NT$9.87 Billion ≈ $311.11 Million	-1.42pp
2022-12-31	3.40%	NT$326.86 Million ≈ $10.30 Million	NT$9.60 Billion ≈ $302.47 Million	-0.60pp
2021-12-31	4.01%	NT$372.65 Million ≈ $11.74 Million	NT$9.30 Billion ≈ $292.89 Million	+0.35pp
2020-12-31	3.66%	NT$342.40 Million ≈ $10.79 Million	NT$9.36 Billion ≈ $294.92 Million	-1.39pp
2019-12-31	5.05%	NT$482.62 Million ≈ $15.21 Million	NT$9.55 Billion ≈ $300.96 Million	-0.81pp
2018-12-31	5.86%	NT$530.83 Million ≈ $16.72 Million	NT$9.05 Billion ≈ $285.22 Million	-12.77pp
2017-12-31	18.64%	NT$1.77 Billion ≈ $55.82 Million	NT$9.51 Billion ≈ $299.52 Million	--

pp = percentage points

About TTY Biopharm Co Ltd

TWO:4105 Taiwan Drug Manufacturers - Specialty & Generic

Market Cap

$600.07 Million

NT$19.05 Billion TWD

Market Cap Rank

#11276 Global

#401 in Taiwan

Share Price

NT$76.60

Change (1 day)

+0.13%

52-Week Range

NT$72.10 - NT$86.30

All Time High

NT$97.91